ImmixBiowas founded in 2012 by a driven physician/scientist, a world-renownpharmacology expert, a seasoned biotechnology patent expert and an impact-drivenfounding family office.

Since then, we have demonstrated a consistent track record of execution yielding over100 patients treated in clinical trials advancing toward FDA approval submissions inrelapsed/refractory AL Amyloidosis, relapsed/refractory multiple myeloma, and relapsed/refractory solid tumors across clinical trials including NEXICART-1(NCT04720313) for our next-generation CAR-T cell therapy NXC-201, and IMMINENT-01 (NCT05840835) for our tissue specific therapeutic IMX-110 combined with PD-1.Our clinical results have been presented at premier venues including: American Society for Gene and Cell Therapy, International Myeloma Society, and published in Clinical Cancer Research, Haema to logica and others.

We are fortunate to report that NXC-201 initial response rates of 95% and 100% have been observed from the Phase 1b/2a NEXICART-1 (NCT04720313) studyin patientswith multiple myeloma and AL amyloidosis, respectively (as of July 17, 2023). NXC-201has the potential to be the world’s first out-patient CAR-T and has been awarded Orphan Drug Designation (ODD) by the FDA in both multiple myeloma and ALA my loidosis. Our lead tissue specific therapeutic IMX-110 is in Phase 1b/2a clinical trials as a monotherapy and IMMINENT-01 (NCT05840835) combination clinical trial with BeiGene’s anti-PD-1 antibody tisleli zumab. IMX-110 has been awarded ODD and Rare Pediatric Disease Designation (RPDD) by the FDA.

Accelerated by our team’s unrelenting drive and expertise across cell therapy and other modalities as well as indications, paired with our execution track record, we believe weare uniquely positioned to effect a better future for patient communicates around the globe.